Table: Jcr Pharmaceuticals -2023/24 parent results
May 10 (Reuters)-
Jcr Pharmaceuticals Co., Ltd.
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2024 Mar 31, 2023 Mar 31, 2025 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Sales 42.87 34.34
(+24.8 pct) (-32.8 pct)
Operating 7.55 5.10
(+48.2 pct) (-74.7 pct)
Recurring 8.05 5.28
(+52.3 pct) (-74.1 pct)
Net 6.36 3.69
(+72.6 pct) (-74.5 pct)
EPS 51.00 yen 29.67 yen
EPS Diluted 50.76 yen 29.54 yen
Ann Div 20.00 yen 20.00 yen 20.00 yen
-Q2 Div 10.00 yen 10.00 yen 10.00 yen
-Q4 Div 10.00 yen 10.00 yen 10.00 yen
NOTE - Jcr Pharmaceuticals Co., Ltd..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4552.T
Recent news on JCR Pharmaceuticals
See all newsBrief: JCR Pharmaceuticals Receives Marketing Authorization In Kuwait For Izcargo
Italfarmaco And Jcr Pharmaceuticals Enter Into Exclusive License Agreement For Jr-141 In United States, Europe, And Latin America
Brief: Jcr Pharmaceuticals Receives Orphan Drug Designation For Givinostat In Japan
Brief: Medipal & JCR Dose First Patient In Global Phase I/II Trial OF JR-446 For Mucopolysaccharidosis Type IIIB
Table: Jcr Pharmaceuticals -Q1 group results